Share Name Share Symbol Market Type Share ISIN Share Description
Evgen Pharma Plc LSE:EVG London Ordinary Share GB00BSVYN304 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 7.45 7.30 7.60 7.45 7.45 7.45 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -3.1 -2.7 - 10

Evgen Pharma Share Discussion Threads

Showing 1551 to 1575 of 1850 messages
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
DateSubjectAuthorDiscuss
12/9/2019
11:50
diamondstar1 - the company announced that the last data was collected end of August and that results would be Q4. I suspect end of October. A good article worth a read is; Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential hTTps://www.hindawi.com/journals/omcl/2019/6218239/
pdt
12/9/2019
11:31
Hi there, I’m totally new to this Evgen blog. Have not invested as yet, but I am potentially interested. Firstly, the question I’m asking is when the results of the Ph2 trial will be released? Quick check on clinicaltrials.gov shows that the study sites are active, but have stopped recruiting. Thus, the study has completed recruiting the last patient in early Sept as my guess. Since the patients are dosed on SFX-01 300mg twice daily for 4 weeks, and followed up for Primary Endpoints for a total of 4 weeks, the estimated study completion date should be end-Sept, or perhaps early October. Once study is completed, there will be intensive activity in collecting all relevant clinical trial data, quality checking the data, and producing tables and listings. This activity towards database lock usually takes 4-6 weeks and should span across the whole of October, possibly the first half of November. Hence, my target date for disclosure of the Ph2 SAH results would be mid November. It looks to me like we are about 2 months away from finding out the Ph2 results. Interesting times ahead!
diamondstar1
12/9/2019
09:46
Blakeysangel - setting aside one's commercial hopes for SFX-01, I and am I sure others wish you all the very best.
snowyflake
12/9/2019
09:25
Blakeysangel - it is great to hear your news! It is also encouraging for the prospects of the next trial. To be viewed as a success they are looking for about 8 months of PFS. I think Blakeysangel must be on about 15 months and when the trial results were announced there was someone on 14 months. And some 13 people on the compassionate use programme of 6 months plus duration. I believe the company hopes for even better results overall from the new trial since it will be positioned, at an earlier stage, as a second line treatment after CDK4/6. Combined with excellent safety and low side effects I would have thought that a partner may be interested in this next trial. More information should be disclosed at the Barcelona event at the end of this month. Exciting times for Evgen especially with the SAH results also due in Q4.
pdt
11/9/2019
14:52
Your positive attitude is infectious!
nobbygnome
11/9/2019
14:15
Hi Nobby, Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀
blakeysangel
11/9/2019
14:01
Hi Nobby, Just nausea but the that wears off after a couple of hours, I’m tired but that could be my other meds. I have a good quality of life which is what it’s about..just off to the seaside so alls good 😀😀
blakeysangel
11/9/2019
12:46
Good news! Do you have any discernible side effects from SFX01?
nobbygnome
11/9/2019
12:42
Hi, Onco appointment done today and continuing on Stem SFX01 for at least another 2 months till next scan... feeling happy!! Just need the Share price rise! 😀😀😀
blakeysangel
06/9/2019
18:35
I am a new shareholder as of yesterday and have read the latest year's accounts. The last two placings have each been at higher prices - somewhat unusual one may think - that shows confidence in the company and what the directors are trying to achieve on the part of the placees. The directors say that the company, on current estimates, is funded until after 2020; note after 2020. Like solicitors and other professionals, not all doctors are honest but I personally rate these directors. The SFX-01 clinical trial results should be released in Q4 2019- i.e. anytime from and including this October until the end of December but I guess pre- Christmas as the backstop (that hateful word!!). Also, the directors, unlike those of so many junior companies, are not taking inordinate salaries and treating the company as their thiefdom - so often causing a company to be attacked by the rogue bloggers and thus destroying share value. The stock could have an upward move soon.
snowyflake
06/9/2019
18:19
Due a move upwards
shares188
05/9/2019
09:09
I agree - clearly very interesting news and fascinating too. I am looking forward to seeing where this ends up in the years ahead.
lovewinshatelosses
05/9/2019
08:26
Today's news release is impressive. SFX-01 could prove of use beyond assisting autistic youngsters - say MS and other neurological problems.
snowyflake
29/8/2019
05:58
It was a nothing RNS. So the last patient last visit happened; I am not sure that is worth RNSing. I guess we know that patient at least survived through to the end, although of course mortality is not a primary end point!
nobbygnome
28/8/2019
22:31
Even better for us then. Nimodipine was the last approved drug for SAH 30yrs ago, with making just marginal improvement to patients. Any significant improvement for patients using SFX-01 will be transformational.
90005nelson
28/8/2019
22:17
there are other results due..Sept.
babbler
28/8/2019
20:38
Too much emphasis on the sellers, when it's the first piece of liquidity since the last placing. Timeline is early October around six weeks away, which is a long time on AIM but that gives plenty of opportunities to add to one's position, if wanted. As we get nearer to the results the share price will rise in anticipation.
90005nelson
28/8/2019
18:54
I agree - the RNS was not full of any great drama or fanfare (nor should they be IMO), but I am struggling to see what justified any drop at all to be honest. AIM is a funny old place. I might be tempted to have another small top up if this drops back to circa 15p, but the wiser decision might just be to sit tight and await full results...
lovewinshatelosses
28/8/2019
15:39
which part were they not impressed with?
zed2002
28/8/2019
14:41
Market has not been very impressed with the RNS IMO
buywell3
28/8/2019
13:39
Bloody crazy drop due to impatience.
babbler
28/8/2019
08:44
These will have a big run to the SAH results.
hsm12
27/8/2019
16:38
👍👍
nobbygnome
27/8/2019
16:27
Hi everyone, Just a little update to say I’m still on sfx01 next see my Onco on 11th September, that’s 452 days on this. Hoping for good results for SAH. 😀😀
blakeysangel
27/8/2019
13:41
I've bought back in, hopefully,I've timed it right this time!!
crapcrap
Chat Pages: 74  73  72  71  70  69  68  67  66  65  64  63  Older
Your Recent History
LSE
EVG
Evgen Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191210 10:44:49